1. Introduction {#s0005}
===============

Low back pain (LBP) is a highly prevalent health problem around the world ([@bb0135]), affecting 50% to 85% of people at some point in life ([@bb0025]). According to the Global Burden of Disease Study in 2013, LBP ranked first in the top ten causes of years lived with disability (YLDs) ([@bb0225]). When LBP persists for \> 6 months ([@bb0145], [@bb0220]), it is classified as chronic low back pain (CLBP), which leads to considerable health care costs ([@bb0050]). Since the precise causes and origins of CLBP are unknown to 90% of patients ([@bb0145]), therapeutic methods targeting LBP symptoms are often nonspecific and ineffective.

Recently, neuroimaging techniques have been used to advance our understanding of back pain mechanisms ([@bb0055], [@bb0140], [@bb0150]). In vivo magnetic resonance spectroscopy (MRS) is a non-invasive brain imaging method that can explore metabolic concentrations within certain brain regions. MRS detects radiofrequency signals generated by the magnetic nuclear spins of magnetically active nuclei such as protons, phosphorus, carbon and fluorine, which are excited by external magnetic fields ([@bb0060], [@bb0070]). Compared with other nuclei, proton nuclei (^1^H) are widely used in MRS studies because of their high magnetic sensitivity and natural abundance in tissues ([@bb0030], [@bb0210]). Another benefit of in vivo ^1^H MRS is that it can be conducted in clinical MRI scanners without any additional hardware ([@bb0155]).

Unlike traditional functional MRI, which obtains a spatial map of brain activity, ^1^H MRS voxel placement generates a graphical spectrum of specific regions of the brain ([@bb0120]). The peaks on the spectra represent various cerebral metabolites, including *N*-acetyl-aspartate (NAA), choline (Cho), creatine (Cr), myo-inositol (mI), glutamate (Glu), glutamine (Gln), gamma-aminobutyric acid (GABA) and glucose (Glc). Concentration changes of these metabolites are associated with numerous neurological diseases ([@bb0005], [@bb0035], [@bb0230]), and can sometimes be detected prior to the onset of symptoms ([@bb0075]).

Over the past two decades, a growing number of proton magnetic resonance spectroscopy (^1^H MRS) studies have been applied to investigate biochemical changes in individuals with CLBP. Although results from these studies have shown that CLBP patients exhibit altered ^1^H MRS signal changes in different brain regions, some of the results obtained appear contradictory. Therefore, we performed this systematic review of previous ^1^H MRS studies on CLBP to summarize the biochemical changes in brain regions of interest and to explore potential reasons for those inconsistent findings.

2. Material and methods {#s0010}
=======================

We conducted a systematic search of published studies in PubMed and EMBASE from 1980 to March 2016. The Medical Subject Headings were "magnetic resonance spectroscopy" and "back pain". The search strategy also included key words such as "magnetic resonance spectroscopy", "MRS", "spectroscopy" and "back pain" to identify relevant studies. No language restrictions were applied. The reference lists of the selected articles were also reviewed to search for additional relevant studies. The protocol for this review was registered on PROSPERO (<http://www.crd.york.ac.uk/PROSPERO;> CRD42016045845).

Titles and abstracts of potentially relevant studies were examined to determine whether they fulfilled the following inclusion criteria: (1) Studies compared LBP patients with healthy controls, and (2) studies employed ^1^H MRS to measure metabolite concentrations in the brain. We excluded studies that (1) did not present original data, and (2) did not recruit LBP patients. After reviewing the full texts, one study was excluded because half of the patients in the study did not present with low back pain symptoms.

Data extraction was performed for subject and control numbers, gender, age, diagnostic tools, duration of LBP symptoms, comorbidities with LBP, medications, clinical measurements, metabolites studied, brain regions of interest, voxels of interest, MR scanner devices, magnetic field strengths, MRS sequences, repetition times, echo times, spectral analysis software, metabolite quantification methods (absolute quantification or ratios to Cr), and data inclusion criteria.

3. Results {#s0015}
==========

Our literature search yielded 271 potentially relevant studies on patients with CLBP and healthy controls. 262 studies were excluded for reasons listed in [Fig. 1](#f0005){ref-type="fig"}. [Table 1](#t0005){ref-type="table"}, [Table 2](#t0010){ref-type="table"} and [Fig. 2](#f0010){ref-type="fig"} summarize the characteristics of the 9 included studies.

3.1. Subjects {#s0020}
-------------

The 9 studies recruited a total of 135 CLBP subjects and 137 healthy controls. All of the studies except for one study ([@bb0205]) reported subject numbers by sex, which showed that the majority of subjects were females. For diagnosis of CLBP, three of the included studies adopted the diagnostic criteria of Merskey and Bogduk ([@bb0090], [@bb0095], [@bb0100]), and two studies utilized classification from the International Association for the Study of Pain ([@bb0095], [@bb0205]). All of the patients presented with LBP for \> 6 months. Four out of nine studies mentioned the comorbidities of CLBP; one study was associated with anxiety ([@bb0095]), another focused on depression ([@bb0100]), one study reported seven patients with radiating leg pain, and another study ([@bb0200]) reported subjects with radiating pain in the buttocks and left leg. About 30% of all patients refrained from medication for at least 24 h before the study.

3.2. MRS method {#s0025}
---------------

Two studies collected data using multi-voxel MR spectroscopy imaging ([@bb0200], [@bb0195]), whereas seven used single voxel spectroscopy (SVS) locations to analyze individual data ([@bb0090], [@bb0095], [@bb0100], [@bb0110], [@bb0105], [@bb0130], [@bb0205]). Five studies were performed using a 3.0 T MRI scanner ([@bb0110], [@bb0105], [@bb0130], [@bb0200], [@bb0195]), and four studies utilized a 1.5 T scanner ([@bb0090], [@bb0095], [@bb0100], [@bb0205]). Four studies used stimulated echo acquisition mode sequences (STEAM) ([@bb0090], [@bb0095], [@bb0100], [@bb0205]), five studies used point resolved spectroscopy sequences (PRESS) ([@bb0110], [@bb0105], [@bb0130], [@bb0200], [@bb0195]) and two also used MEscher-GArwood Point RESolved Spectroscopy (MEGA-PRESS) ([@bb0110], [@bb0130]). Repetition times ranged from 500 to 2500 ms. Echo times ranged from 12 to 68 ms.

3.3. Spectral analysis {#s0030}
----------------------

Metabolite concentrations were calculated using LCModel in four studies ([@bb0110], [@bb0105], [@bb0200], [@bb0195]), jMRUI package in one study ([@bb0110]), and Scion Image analysis package in three studies ([@bb0090], [@bb0095], [@bb0100]). Statistical Classification Strategy was specified in one study ([@bb0205]). Data inclusion criteria of two of the studies were (1) total brain volume \> 75%, (2) a SNR \> 10, and (3) Cramer-Rao bounds for each neurochemical \< 20% ([@bb0200], [@bb0195]). In one study, statistical analysis was only conducted for data that exhibited (1) FWHM~NAA~ \< 10 Hz, and (2) CRLB~Gln~ \< 30% for Gln and Glx concentrations ([@bb0105]).

3.4. Cerebral metabolites {#s0035}
-------------------------

Cerebral metabolites were reported as a ratio to Cr in five studies ([@bb0090], [@bb0095], [@bb0100], [@bb0110], [@bb0130]) and absolute concentrations in three studies ([@bb0105], [@bb0200], [@bb0195]). Three studies determined the absolute concentrations; two studies utilized LCModel to calculate the metabolite concentrations and corrected the LCModel output for the estimated brain tissue fraction ([@bb0200], [@bb0195]), while the other study used the water signal reference method that multiplied the ratio of metabolic intensities to water signal intensities (assessed by LCModel) with the water concentration in brain tissue and corrected for factors such as relaxation ([@bb0105]).

### 3.4.1. NAA {#s0040}

Studies reported reductions of NAA in five brain regions, including the dorsolateral prefrontal cortex (DLPFC), right primary motor cortex (M1), left somatosensory cortex (SSC), left anterior insula (aI) and anterior cingulate cortex (ACC) ([@bb0090], [@bb0105], [@bb0200], [@bb0195]). There were no significant differences in concentrations between patients and controls in the left M1, right SSC, thalamus, cingulate, insula, sensorimotor cortex (SMC), orbital frontal cortex (OFC), and visual cortex (VC) ([@bb0090], [@bb0200], [@bb0195]).

### 3.4.2. Glu, Gln, Glx and GABA {#s0045}

One study observed a significant decrease in Glu in patients\' ACC ([@bb0105]). There were no significant changes of Glu/GABA ratios in the ACC and insula ([@bb0130]). In the SSC, Glx concentrations were not significantly changed ([@bb0195]). Additionally, patients did not show any comparable Glx and GABA interrelations in the ACC, left insula, and posterior cortex ([@bb0110]).

### 3.4.3. mI {#s0050}

Four studies investigated alterations of mI; it was reduced in the ACC and thalamus ([@bb0105]), whereas in the DLPFC, OFC, cingulate and M1, concentrations of mI were not significantly different between CLBP and control groups ([@bb0095], [@bb0200]). In one study targeted at the SSC, the authors found significant correlations between mI in the left and right SSC of CLBP patients when compared to healthy controls ([@bb0195]).

### 3.4.4. Cho {#s0055}

Three studies investigated Cho changes in CLBP patients; there were no significant changes in the regions of DLPFC, thalamus, cingulate, insula, SMC, OFC, VC, left aI, left thalamus and ACC ([@bb0090], [@bb0105]). Decreased Cho was observed in the right SSC in CLBP patients as compared to controls in one study ([@bb0195]).

### 3.4.5. Glc {#s0060}

One study investigated the Glc changes in CLBP patients, and reported reductions of Glc in the DLPFC ([@bb0090]).

### 3.4.6. Cr {#s0065}

One study investigated the Cr changes in CLBP patients, and reported no significant changes in Cr between groups in the left aI, left thalamus and ACC ([@bb0105]).

Studies demonstrated neurochemical alterations in six brain regions of CLBP patients compared to healthy controls: 1) decreased *N*-acetyl-aspartate (NAA) and glucose (Glc) in the dorsolateral prefrontal cortex (DLPFC); 2) significantly decreased Glu and reduced NAA and myo-inositol (mI) in the anterior cingulate cortex (ACC); 3) reduced NAA in the left anterior insula (aI); 4) decreased MI in the thalamus (Th); 5) significantly decreased NAA in the left somatosensory cortex (SSC) and decreased choline (Cho) in the right SSC; and 6) decreased NAA in the right primary motor cortex (M1).

3.5. Association between the clinical measurements and the cerebral metabolites {#s0070}
-------------------------------------------------------------------------------

### 3.5.1. Pain {#s0075}

Several studies utilized the visual analog scale (VAS) to rate patients\' pain intensity, and six studies also measured pain using the Short Form McGill Pain Questionnaire (SF-MPQ) ([@bb0090], [@bb0095], [@bb0100], [@bb0200], [@bb0195], [@bb0205]). NAA levels in SSC were found to be negatively correlated with pain duration ([@bb0195]). Reductions of NAA in the right DLPFC were negatively associated with pain behavior (as measured by total SF-MPQ scores) ([@bb0100]). In addition, studies also showed that pain intensity was positively correlated with Glu levels in the insula and Glx levels in the right SSC, while pain intensity was negatively correlated with GABA concentrations in the insula ([@bb0130], [@bb0195]). No significant correlations were detected between neurochemicals (NAA, mI) and pain characteristics (VAS and SF-MPQ) in the M1 ([@bb0200]).

### 3.5.2. Anxiety {#s0080}

In addition to CLBP related measurements, two studies used the State--Trait Anxiety Inventory (STAI) to measure anxiety states ([@bb0090], [@bb0095]). One study found significant increases of NAA in the OFC of high anxiety controls compared to high anxiety CLBP patients, and of low anxiety CLBP patients compared to high anxiety CLBP patients ([@bb0095]). Another study using the Hospital Anxiety and Depression Scale (HADS) reported anxiety as a causal variable for reduced Glu in the ACC ([@bb0130]).

### 3.5.3. Depression {#s0085}

Participants in three studies ([@bb0100], [@bb0200], [@bb0195]) completed the Beck Depression Inventory (BDI). NAA levels in the right DLPFC were negatively correlated with depressive symptoms as measured by BDI scores ([@bb0100]). One study used the Hospital Anxiety and Depression Scale (HADS) ([@bb0130]), and found depression and age could predict reduced GABA in the ACC.

4. Discussion {#s0090}
=============

In this study, we reviewed the previous ^1^H MRS studies on CLBP to summarize the biochemical changes in CLBP patients. Seven of the nine studies reviewed in this paper reported statistical differences in brain metabolites in the thalamus, insula, SSC, ACC, DLPFC and M1 between healthy controls and patients, indicating brain chemical changes in brain regions associated with pain processing ([@bb0015], [@bb0165], [@bb0185]).

Additionally, we found reduction of NAA in five brain regions of CLPB patients, and studies focused specifically on comorbid anxiety and depression ([@bb0095], [@bb0100]) found exaggerated effects ([@bb0235]). NAA is the acetylated form of the amino acid aspartate, and is present in very high concentrations in brain neurons ([@bb0215]). It has been recognized as a neuronal marker ([@bb0020], [@bb0085]), but its function remains controversial. One hypothesis proposed for the role of NAA in the nervous system is that NAA serves as an immediate precursor for the neurotransmitter *N*-acetylaspartylglutamate, and NAA is reportedly reduced in neurodegenerative diseases ([@bb0160]), which we ascribe to neuronal loss and degeneration. In addition, several studies suggesting that significant brain atrophy exists in the right thalamus ([@bb0010]), SSC (Schmidt-Wilcke et al.) and DLPFC ([@bb0010], [@bb0190]) of CLBP patients seem to provide fairly compelling evidence to this assumption. However, another documented function of NAA is that it is involved in brain glucose consumption ([@bb0175]), which is also decreased in the DLPFC of CLBP patients. We thus believe that reduced NAA in low back pain patients may indicate that energy metabolism is altered as well.

We also found a reduction of mI in CLBP patients. MI is primarily present in glial cells ([@bb0040]) and has been proposed as a marker for the density of glial cells ([@bb0085]). Studies on the biosynthesis of mI reported that it\'s generated in the phosphoinositide (PI) second messenger system from a key molecule in cellular signal transduction phosphatidylinositol 4,5-bisphosphate (PIP2) ([@bb0045]). Thus, a decrease in mI may suggest a loss of glial cells or an alteration in glial metabolism caused by LBP.

The lower Cho concentration in the SSC of patients with LBP was an unexpected finding because Cho levels are elevated in most neurological diseases, including neoplasms, demyelination and gliosis ([@bb0065], [@bb0125]). Cho is a precursor of acetylcholine (Ach) ([@bb0180]), which is a component of cell membranes. Therefore, we think the low concentration of Cho in the SSC can be explained by an increased uptake of Cho for the building of cell membranes ([@bb0115]) and for maintaining cell membrane integrity.

Results from our study showed evidence of decreased Glu in the ACC of patients with CLBP, which is the most abundant excitatory neurotransmitter in the brain ([@bb0240]). In contrast to the results of Gussew and colleagues ([@bb0105]), Grachev and colleagues ([@bb0090]) reported no changes in Glu in the cingulate of CLBP patients. This contradictory finding could be attributed to the methodological differences between the two studies. Gussew and colleagues investigated absolute neurochemical concentrations of Glu while Grachev and colleagues focused on Glu ratios to creatine. In addition, patients in the studies differed in pain intensities and duration of pain symptoms, which may also influence the results.

The Cr ratio method was utilized for spectral quantification in the five studies. The Cr peak is relatively stable, and therefore is commonly used as a concentration reference for comparison. One study indicated no significant differences in Cr resonance in the left aI, left thalamus and ACC. However, this approach should be used with caution because some studies reported alterations of this metabolite in several diseases ([@bb0085]). Thus, further investigations on Cr concentration in CLBP patients in different brain regions are needed.

No significant differences were found in excitatory neurotransmitter GABA levels in CLBP patients compared with healthy controls, despite the role of GABA receptors in the modulation of pain perception ([@bb0080]). This lack of significant findings may be due to extremely low concentrations of GABA in the brain and spectral resonance overlaps with peaks of other metabolites, which cannot be resolved unless spectral editing sequences like MEGA-PRESS ([@bb0170]) are utilized.

There are several limitations in our study. First, there are relatively few subjects in each cohort, and confounding factors, such as anxiety and depression, made it difficult to identify specific biochemical markers of CLBP. Secondly, in eight studies, almost half of the patients had received prior treatment for CLBP. Although some of the patients refrained from medications for at least 24 h before the study, it\'s not clear whether this eliminates the influence caused by long-term medication use. Finally, although these MRS studies have detected neurochemical alterations in these brain regions, the underlying causes of these metabolic changes are not fully understood. Therefore, further investigation is needed to explore the pathophysiological relationship between the neurochemical alterations and CLBP.

5. Conclusion {#s0095}
=============

In summary, our study provides evidence for alterations in the biochemical profile of the brain in patients with CLBP, which suggest that biochemical changes may play a significant role in the manifestation of CLBP. Future studies need to emphasize therapeutic response and the relationships between brain metabolites and functions.
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###### 

Patient characteristics.

Table 1

  Study       Patients (M)   Age mean ± SD   Duration of illness (yrs)   Comorbidity (N)                                      Stop medication   VAS score                Other clinical measurement
  ----------- -------------- --------------- --------------------------- ---------------------------------------------------- ----------------- ------------------------ --------------------------------
  [@bb0090]   9 (7)          45 ± 6          9 ± 5                       NM                                                   ≥ 24 h            61.81 ± 17.18 (of 100)   SF-MPQ, STAI
  [@bb0095]   12 (9)         47.5 ± 5.6      8.86 ± 4.4                  Anxiety                                              ≥ 24 h            61.81 ± 17.18 (of 100)   SF-MPQ, STAI
  [@bb0100]   10 (5)         49 ± 11         12.6 ± 6                    Depression                                           ≥ 24 h            64.6 ± 14.4 (of 100)     BDI, SF-MPQ
  [@bb0105]   10 (2)         22--52          1--5                        NM                                                   ≥ 24 h            4.1 ± 1.1                LSSI
  [@bb0110]   13 (1)         54 ± 8          NM                          NM                                                   NM                NM                       NM
  [@bb0130]   19 (3)         55.3            13.3 ± 12.1                 NM                                                   NM                6.3 ± 1.3                HADS-D, HADS-A
  [@bb0195]   11 (0)         33.6 ± 10.6     10.6 ± 8.3                  Radiating leg pain (7)                               NM                5.9 ± 1.4                PE, SF-MPQ, FABQ, MODS, BDI
  [@bb0200]   19 (4)         46.1 ± 11.3     8.8 ± 7.2                   Radiating pain in buttocks (9) and/or left leg (4)   NM                4.5 ± 1.9                SF-MPQ, FABQ, MODS, BDI
  [@bb0205]   32 (NM)        NM              ≥ 0.5                       NM                                                   No                NM                       SF-MPQ, DASS, RMDQ, PSEQ, LSSI

Abbreviation: BDI, Beck Depression Inventory; DASS, Depression Anxiety Stress Scales; FABQ, Fear-Avoidance Belief Questionnaire; HADS-A, Hospital Anxiety and Depression Scale - Anxiety subscale; HADS-D, Hospital Anxiety and Depression Scale - Depression subscale; LSSI, lumbosacral spine imaging; M, male; MODS, Modified Oswestry Disability Scale; N, number; NM, not mentioned; PE, Physical examination; PSEQ, Pain Self-Efficacy Questionnaire; RMDQ, Roland & Morris Disability Questionnaire; SF-MPQ, Short Form McGill Pain Questionnaire; STAI, State--Trait Anxiety Inventory; VAS, visual analog scale.

###### 

Summary of methods and results.

Table 2

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Study       Metabolites                              ROI                                       VOI   Field strength   MRS sequence       TR (ms)     TE (ms)   Results
  ----------- ---------------------------------------- ----------------------------------------- ----- ---------------- ------------------ ----------- --------- -----------------------------------------------------------
  [@bb0090]   NAA, Cho, GABA, Glu, Gln, Glc, Lac       DLPFC, Th, cingulate, Ins, SMC, OFC, VC   SVS   1.5 T            STEAM              500         12        NAA and Glc ↓ in DLPFC

  [@bb0095]   NAA, Cho, GABA, Glu, Gln, Glc, mI, Lac   DLPFC, OFC, Th, cingulate                 SVS   1.5 T            STEAM              1500        30        NAA ↑ in OFC between high anxiety groups

  [@bb0100]   NAA                                      DLPFC, ACC, OFC, Th                       SVS   1.5 T            STEAM              1500        30        NAA ↓ in the right DLPFC of CLBP patients with depression

  [@bb0105]   NAA, Cr, Cho, mI, Glu, Gln               aI (L), ACC, Th (L)                       SVS   3 T              PRESS              2500        30        1\. Glu ↓↓ in the ACC\
                                                                                                                                                                 2. NAA ↓ in left aI and ACC\
                                                                                                                                                                 3. mI ↓ in ACC and left Th

  [@bb0110]   Glx, GABA                                ACC, Ins (L), PC                          SVS   3 T              PRESS/MEGA-PRESS   1800/1800   30/68     NSSD

  [@bb0130]   Glu, GABA                                ACC, Ins                                  SVS   3 T              PRESS/MEGA-PRESS   1800/2000   30/68     NSSD

  [@bb0195]   NAA, Cho, mI, Glx                        SSC                                       MVS   3 T              PRESS              1500        30        1\. NAA ↓↓ in the left SSC\
                                                                                                                                                                 2. Cho ↓ in right SSC

  [@bb0200]   NAA, mI                                  M1                                        MVS   3 T              PRESS              1500        30        NAA ↓ in right M1

  [@bb0205]   Cho, Cr, Glx, mI, NAA                    ACC (L), PFC (L), Th (L)                  SVS   1.5 T            STEAM              1500        25        MRS detected neurochemical changes with high accuracy.
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Abbreviation: ACC, anterior cingulate cortex; aI, anterior insula; Cho, choline; Cr, creatine; DLPFC, dorsolateral prefrontal cortex; GABA, gamma-aminobutyric acid; Glc, glucose; Gln, glutamine; Glu, glutamate; Glx, glutamate and glutamine; Ins, insula; Lac, lactate; MEGA-PRESS, MEscher-GArwood Point RESolved Spectroscopy; mI, myo-inositol; MVS, multiple single voxel spectroscopy; NAA, *N*-acetyl-aspartate; NSSD, non-statistically significant difference; OFC, orbital frontal cortex; PC, posterior cortex; PFC, prefrontal cortex; PRESS, point resolved spectroscopy; ROI, region of interest; SMC, sensorimotor cortex; SSC, somatosensory cortex; STEAM, stimulated echo acquisition mode; SVS, single voxel spectroscopy; TE, echo time; Th, thalamus; TR, repetition time; VC, visual cortex.
